key: cord-0906363-gi3vfi68
authors: Grewelle, R.; De Leo, G.
title: Estimating the Global Infection Fatality Rate of COVID-19
date: 2020-05-18
journal: nan
DOI: 10.1101/2020.05.11.20098780
sha: aa2b335f82281100d08bf3dd47469fe92d4e8b15
doc_id: 906363
cord_uid: gi3vfi68

COVID-19 has become a global pandemic, resulting in nearly three hundred thousand deaths distributed heterogeneously across countries. Estimating the infection fatality rate (IFR) has been elusive due to the presence of asymptomatic or mildly symptomatic infections and lack of testing capacity. We analyze global data to derive the IFR of COVID-19. Estimates of COVID-19 IFR in each country or locality differ due to variable sampling regimes, demographics, and healthcare resources. We present a novel statistical approach based on sampling effort and the reported case fatality rate of each country. The asymptote of this function gives the global IFR. Applying this asymptotic estimator to cumulative COVID-19 data from 139 countries reveals a global IFR of 1.04% (CI: 0.77%,1.38%). Deviation of countries' reported CFR from the estimator does not correlate with demography or per capita GDP, suggesting variation is due to differing testing regimes or reporting guidelines by country. Estimates of IFR through seroprevalence studies and point estimates from case studies or sub-sampled populations are limited by sample coverage and cannot inform a global IFR, as mortality is known to vary dramatically by age and treatment availability. Our estimated IFR aligns with many previous estimates and is the first attempt at a global estimate of COVID-19 IFR.

SARS-COV-2 emerged from Wuhan, China at the end of 2019 and has become a global pandemic with over four million confirmed infections and nearly three-hundred thousand associated deaths [1, 2, 3, 4, 5] . Now spreading in all continents but Antarctica, the disease associated with this novel virus (COVID- 5 19) is a risk to people of all nations [6] . Yet, this risk is known to vary widely with access to healthcare and demographic traits [3, 4, 7] . Although the extent of sub-lethal impacts of the virus are still not known, deaths attributed to infection are of great concern and are used as a measure of disease burden, being a more reliable metric than the number of confirmed infections as the latter is 10 notoriously dependent on testing capacity [8] .

Counter-measures to inhibit the transmission of the virus are in place in most countries, and economic decline has resulted from the closure of businesses and travel restrictions [9, 10] . With pressure to re-open economies to reduce job losses and downstream repercussions, leaders of countries and localities are 15 weighing the health risks of COVID-19 with economic risks of control measures [11] . The linchpin for policymakers is often the risk of mortality upon infection.

Reported data from countries reveals a large spread in case fatality rate (CFR) from 0.5-15% [12] . This rate is given by the number of deaths per confirmed infection. The vast difference in the reported CFR by country is primarily a 20 product of testing availability [13, 14] . In the early phases of the outbreak and in countries where testing kits were limited, only hospitalized patients with advanced COVID-19 symptoms have been tested. Therefore, the CFR is an inflated estimate of the infection fatality rate (IFR) because many infections in the population are unidentified [15, 16] . This inflation is intrinsic for reported 25 data across all countries, though it is much smaller for countries that have greater testing capacity such that individuals with mild or no symptoms are tested.

To understand how dramatic this inflation is, an increasing number of serological studies has contrasted the number of active infections confirmed with 30 As testing captures a greater proportion of the population, the estimated 60 CFR better approximates the IFR because the individuals with mild or no symptoms and more likely to recover are included in the confirmed infections.

With increasing testing capacity, the sample prevalence decreases. Testing capacity is relative to the case load in the country. A country with 1000 true infections requires more tests than a country with 100 true infections for similar 65 case estimates. Because the true case load of COVID-19 is unknown in each country, we estimate testing capacity, C, as tests performed per positive case.

This estimate provides a metric of the availability of tests relative to the case load, indicating relative testing capacity. 

ρ is the sample prevalence. It is true that as the number of total tests increases and approaches a randomized sample of the whole population, the 75 number of positive tests better estimates the active true case load in the population, P pop . The relation between ρ and the estimate of the true case load differs by testing regimes and cannot be fully known, but if testing prioritizes individuals with symptoms or at risk of infection, convergence of the known positive, P test , to the true positive, P pop , approximates an exponential decay 80 with decay constant k, as shown in SI 1.

Despite differences in testing regimes in each country, the approximation in equation 3 becomes closer to exact as testing capacity increases. As C → ∞,

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05. 11.20098780 doi: medRxiv preprint P test → P pop . From equation 3 the following is true:

Log transformation yields:

Assuming COVID-19 attributed deaths are more reliably estimated than COVID-19 cases, we can derive a relation to the true IFR from the reported CFR.

Substitution of this relation in equation 5 gives

which is equivalent to 90 log(CF R) = log(IF R) + k C (9) Equation 9 reveals that the y-intercept of a linear regression of C −1 = ρ and log transformed CFR can be exponentiated to yield the true IFR. We compile a comprehensive list of all countries that have recorded COVID-19 associated deaths as of April 21, 2020. After calculating the CFR, P test , ρ, and C for each country using cumulative cases, deaths, and tests performed, a weighted linear 95 regression was performed according to equation 10:

Countries are inverse variance weighted (w i ); in the absence of variance attributed to testing regimes for each country, we assume homoscedasticity and 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint variance of each estimate is inversely proportional to the number of tests performed (SI 2). The right panel is the plot of testing capacity and CFR with 100 the regression achieved by equation 9 overlayed on the plot. The exponential of the y-intercept (at ρ = 0) in the regression corresponds to the asymptote as

The variance-covariance matrix (V) of the parameter estimates, log(ÎF R) andk, is calculated as

where H −1 is the inverted numerically estimated Hessian, RSS is the weighted 

The transformation of the data from 139 countries according to equation 9 yields a linear relationship between sample prevalence (ρ) and the logarithm of reported CFR for each country.

The weighted regression produces estimates for the y-intercept at −4.40 = log(ÎF R) and slope at 8.80 =k. R 2 = 0.5524, signaling that the relationship 125 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Figure S1 for linear scale). The asymptote as C → ∞ corresponds to the estimated global IFR. Black dashed lines represent 95 % confidence intervals.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint described between testing capacity and reported CFR explains over 55 % of the variation in the reported data. Exponentiating the y-intercept estimate yields a global IFR of 0.0123, or 1.23%. This corresponds to the asymptote seen in panel B of Figure 2 as C → ∞. 95% confidence intervals for IF R and k are (0.0096, 0.0157) and (8. 1, 9.5) , respectively. Because recent evidence suggests 130 up to 15% false negative rate for rapid SARS-COV-2 PCR based tests, we adjust the calculations of capacity and CFR for each country and perform and adjusted regression which yields an intercept at −4.56 = log(ÎF R). The adjusted IFR accounting for false negative tests is 1.04%. Due to the uncertainty associated with the 15% false negative approximation, we retain the larger con-135 fidence intervals of the unadjusted estimate to give a 95% confidence interval of (0.0077, 0.0138). These results support a global IFR between 0.77% and 1.38%.

This estimate implicitly accounts for asymptomatic cases and country-level differences in demography and testing regimes, and as such, it represents a global average.

Reported here is a function relating testing capacity to the CFR estimate, and deviation from that function by a country may convey information of the underlying IFR. Placement above the regression line in panel B of Figure 2 could indicate higher national true IFR than the expected global average. Among the most reliable factors to predict IFR from COVID-19 are income and the age 145 structure of the population, particularly the proportion of individuals 65 and older [7, 21] . We tested whether the reported CFR for each country was higher than the expected global mean at the corresponding testing capacity. p-values < 0.05 denote a lower CFR than the global mean, while p-values > 0.95 denote a higher CFR than the global mean. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Linear regressions reveal slight trends in favor of a lower CFR with increasing GDP and higher CFR with increasing age. These trends are marginal, and correlation between deviation from the global estimate and these factors is not 155 substantiated. Rather, deviation is likely due to differences in COVID-19 reporting practices, testing, and stage of the epidemic in each country. Table 1 gives a list of the countries deviating significantly from the predicted CFR (all 10 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. Table 2 . Alone, neither GDP nor age were strong 11 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint predictors of a nation's reported CFR. The weak relationships aligned well with the relationships shown in Figure 3 , where CFR increases with an aging populace 175 and decreases with income. Due to the weakness of prediction, these models were not included in model comparison. Four models were compared, expanding on ρ. Age and GDP marginally improved the model fit, suggesting a small but non-significant influence of these factors in a country's CFR. The relationship between age and GDP on a country's IFR are unclear from these results because 180 the most significant predictor of CFR is testing capacity. estimate of IFR in one locality will differ from the IFR in another due to differences in underlying health conditions, demography, and medical treatment.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. .

Rather than understanding the extent of the variability these factors can create in IFR measurements, we derive a new approach to IFR estimation using global data. Provided testing has prioritized people at highest risk of SARS-COV-2 195 infection, the metric of relative testing capacity used in our approach should reflect each country's ability to accurately estimate the true IFR. Despite variation in reporting and testing strategy, we do find a close relationship between testing capacity and reported IFR. Moreover, the relationship aligns well with the predicted relationship given assumptions regarding testing capacity. Trans- Deviation of reported CFR by each country from the global mean estimated from the regression line does not necessarily reflect true differences in national IFR from the global IFR. There is little to no correlation between these devia-210 tions and GDP or age, which are considered proxies of risk for mortality from COVID-19 [7, 21] . Instead, deviations likely represent variation in testing and reporting strategies. Table 1 gives the countries outside of the 90% confidence interval of the estimated global mean at their reported ρ. These countries likely vary from expectation due to testing differences that change estimates of testing 215 capacity or differences in reporting deaths from COVID-19. Additional variation can occur because COVID-19 associated deaths lag diagnosis, so countries early in an epidemic may report a lower than expected CFR.

COVID-19 associated deaths may be positively identified through a PCRbased test or reported if medical diagnostic criteria are met as judged by a physi-220 cian [20] . Due to comorbidities, such as hypertension or diabetes, estimates of COVID-19 deaths have been questioned. Arguments that death coinciding with a positive SARS-COV-2 test does not necessarily meet criteria for a COVID-19 13 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint associated death have been made. Given results of this work that indicate the risk of death to be approximately 1% from COVID-19, which is higher than the 225 risk of death in the same 2-3 week interval from common chronic comorbidities [24, 25] , the probability that a SARS-COV-2 positive death could be attributed to COVID-19 is higher than the probability the death could be attributed to other chronic comorbidities. In an estimate of 0.1% probability of mortality in a 2 week window due to existing comorbidities, the probability that death of an 230 infected patient with a pre-existing condition is primarily due to the existing condition is less than 10% (SI 6). In this case, the reported CFR needs to be adjusted to 90% of its value. In light of this, the vast majority of SARS-COV-2 positive deaths are due in whole or primarily to COVID-19. High reported CFR values are a result of under-counting of positive infections rather than over-235 counting COVID-19 associated deaths. This contrasts needed adjustments in deaths associated with influenza, as the lower IFR of active influenza infections leads to a higher coincidence of mortality due to chronic disease and infection relative to the incidence of influenza associated mortality alone. In some localities it is estimated that COVID-19 associated deaths are under-reported by 240 25-50% because these deaths occur outside of a hospital setting [26] . Underreporting of deaths is likely to outweigh over-reporting due to comorbidities in many localities.

The inflation of reported CFR values can be approximated by testing capacity, as we relate in this study. The remaining 45% of the variation in the 245 data unexplained by the metric of testing capacity used here is likely explained by a mixture of variability in national reporting, testing strategies, and stage of the epidemic with select cases explained by demography, underlying health conditions, income, or availability of treatment. The methods provided in this work and the supplement are easy to translate to other studies when high qual-250 ity data and independent samples are available. We hope this approach can be used to give updated estimates of the global IFR, as deaths due to infection often lag diagnosis. Reported CFR values for some countries in this study are low due to the nascency of viral transmission in the country in April 2020. As 14 .

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint more data becomes available for infections and COVID-19 deaths, case fatality 255 rates can be more reliably approximated, which can be translated to a global IFR. Temporal or regional variation in testing strategy affects the relationship between CFR and testing capacity, therefore cumulative data collected at least 1 month after the first recorded COVID-19 death in each country better represents the relationship than point estimates. Best estimates rely on standardized 260 global reporting practices, though this method is robust despite differences. Of note, some countries have yet to report deaths, and more have yet to report the number of tests administered, including China. Failure to report these estimates impairs resolution of the global IFR, which is crucial in providing a predictive framework for epidemiologists and policy makers to inform appropriate control 265 measures.

The aim of this study was to provide a reliable metric that enables a robust estimate of the global IFR capturing a wide range of variation without accounting for underlying variability that is necessary to give point estimates of the IFR in each locality. Though we provide the first measurement, the es-270 timate of a global IFR of 1.04% is dynamic and can be updated with incoming data. This number is lower than the IFR for the Diamond Princess cruise (2%), whose demography was skewed toward older individuals [18] . The older age of this sample may be partially counterbalanced by the higher income and access to healthcare of the majority of these individuals than the global average. Na-275 tional surveys performed in Iceland have estimated an IFR below 0.6%, which is among the most randomized testing conducted in any nation, though much of these cases have affected a younger group than is representative of the nation [27] . A previous estimate of IFR in China of 0.66% aligns well with projections from Iceland [19] . Seroprevalence studies have inferred widely different 280 estimates of IFR, including a non-random sample of Santa Clara county residents in CA that suggested an IFR of 0.12-0.2% [17] . NYC seroprevalence of grocery shoppers suggests approximately one of every 5 NYC residents has been exposed. Because 0.15% of NYC residents had died from COVID-19 at the time the study was conducted, seroprevalence results yield a city-wide IFR of 0.75%. 285 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint

The variety of IFR estimates reflects study design and underlying risk factors that contribute to COVID-19 mortality. Although randomized seroprevalence surveys will provide the most accurate measurement of local IFR, these surveys cannot be conducted on a global scale, especially if the results of these surveys are to be used proactively to inform control strategies. Much of the current 290 local estimates of IFR are representative of high income areas with high access to treatment. Higher IFR is possible in areas where surveys have not been conducted due to disparity in healthcare access or testing [21] . The IFR reported in this study attempts to capture some of the variability associated with these disparities between countries, which has otherwise been neglected in previous 295 studies.

Most importantly, the realized IFR is dependent on healthcare capacity, which can vary with conditions of the pandemic. High case load can overwhelm hospital staff and resources, leading to high realized IFR. This is a possible explanation for the high departure of Italy's reported CFR from the global 300 estimate for equivalent testing capacity [28] . We estimate the IFR for Italy as 1.91% (SI 7), which is higher than a recent estimate of 1.29% provided by Rinaldi and Paradisi from early data but within their credible interval [29] . The IFR for Italy is likely higher than for countries of equivalent GDP and healthcare access due to the spike in cases that occurred in March 2020 that exhausted 305 hospital resources in the northern regions. Proper control measures and testing can minimize infection spikes to levels that hospitals can manage, reducing the IFR.

REG conceived the study, extracted and analyzed data, developed the meth-310 ods and code, and wrote the manuscript. GDL edited the manuscript and contributed to the analysis and final draft.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. 18 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

It follows that

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Therefore, the following relation is true:

The sample prevalence can be represented as

Substitution yields

The total number of positive test results achieved can be calculated as

From equation S1, the number of cases in the population is

Combining equations S8 and S9 yields

From equation S7 we find

As ρ 0 is dependent on the true prevalence in the population and is the maximum in the set {ρ t }, the sample prevalence at τ can be adjusted to a 20 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint reported sample prevalence ρ that can vary between 0 and 1 rather than 0 and

Denoting ∆ as the quotient of ρ 1 and ρ 0 gives a simplified equation

For P test to converge to P pop as ρ τ → 0, ∆ has a unique real valued solution at e −1 . The equation becomes

The Taylor expansion of e −kρτ at ρ τ = 0 is 1 − kρ τ + O(ρ 2 τ ), therefore supplemental equation 14 can be approximated as 375 P test P pop ≈ e −kρτ (S15) Equation S14 is an exact relation that represents a closed system in which sampling occurs much more quickly than the accumulation of new infections.

Even under slow sampling, convergence to the true population case load occurs at a constant rate. However, when new cases occur at a similar rate to testing, convergence should occur more slowly. Equation S15 has the capacity to capture 380 this property more accurately at high ρ τ (slow sampling) than equation S14 while maintaining the same properties at low ρ τ (high sampling).

ity and the convergence of the positively identified COVID-19 cases and the true number of cases in the population, which is the sum of the identified and 385 unidentified active cases. This relationship will differ with testing regime, as in each locality procedures for administering tests vary, including the frequency of re-testing that occurs. However, the function should approach 1 as C → ∞.

With a higher proportion of symptomatic patients, more information is available 21 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . to prioritize testing, so convergence of the estimate of cases occurs more rapidly with increasing capacity. Ptest Ppop = e −k/C provides a simple function with the desired property of approaching 1 as C → ∞. Use of this equation provides the derivation of equation 9 in the main text, which gives the relationship between CFR and C. Transforming the data by inverting the x-axis and log-transforming the y-axis produces a linear relationship as predicted by equation 9. In this way, 395 the use of equation 3 is supported, though because it is not otherwise empirically verified, its use should not be extended to approximate local case loads.

As mentioned in the main text and here, variation in testing protocol invalidate use of equation 3 at small scales.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint

The linear regression reported in Figure 2 (main text) was performed according to equation 10 with inverse variance weights. Variance in reported CFR values for each country is a function of the sample variance σ 2 i due to testing protocol, specificity, and accuracy, and the number of tests performed

Because sample variance has not been measured for each country, we assume 

The covariance oflog(IF R) andk is reported in the two off-diagonal entries of V. 420 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Figure S1 : Plot of raw data of capacity vs CFR by country with superimposed estimated regression. In contrast to Figure 2 in the main text, the capacity axis is not log-scale. Venezuela is not plotted due to its high capacity.

The R 2 reported from the linear regression in Figure 2 panel A of the main text is given as follows:

RSS is defined as:

TSS is defined as:

The linear regression on the log-transformed data provides a estimated line with normally distributed errors, and the 95% confidence intervals for log(ÎF R)

is easily approximated as log(ÎF R) ± 1.96(0.124), where 0.124 is the standard 25 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. The 95% confidence intervals for the linear regression can be calculated aŝ

Partial derivatives are calculated as

Therefore, the confidence interval simplifies tô

These intervals are reported as the dashed lines in Figure 2 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. 

Therefore, the confidence interval simplifies to

The covariance of the parameters in the linear regression, Cov(α,k), is given by the Hessian-derived variance-covariance matrix, V. However, because of the 445 exponentiation of α to deriveÎF R, the covariance between the parameters no longer applies. Cov(ÎF R,k) = Cov(α,k). Cov(α,k) requires derivation. Let ξ be the log-normally distributed random variable representing IF R with median atÎF R. Let α be the normally distributed random variable representing log(IF R) with mean atα. k is a normally distributed random variable with 450 mean atk. ξ = e α 27 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint

This approximation was verified by monte carlo simulation at 10 7 replicates. Table 1 of the main text. Table 1 of the supplement gives the full list of p-values by country. 465 28 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Continued on next page 29 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Continued on next page 30 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint Continued on next page 31 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. Continued on next page 32 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. Continued on next page 33 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2020. . https://doi.org/10.1101/2020.05.11.20098780 doi: medRxiv preprint tality due to infection from influenza or COVID-19 is approximately 2 weeks, the probability of death from one of the most likely comorbidities like heart disease or diabetes in the two week window is approx. 10 −3 (after diagnosis and 50+ yrs of age, USA) [30] . The harmonic mean of the life expectancy for men (6.7 yrs) and women (7.9 yrs) over 50 diagnosed with heart disease in the USA Assuming contracting an infectious disease is independent of pre-existing con-495 ditions, the probability that the death of a patient with both a pre-existing condition and infection can be assigned primarily to the infection can be calculated. Given a death of a patient with a pre-existing condition (c = death by condition) and positive infection (i = death by infection), the probability the infection can be assigned the primary contributor to death is: 500 P r(i) = P r(i

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: a descriptive study

Clinical characteristics of coronavirus disease 2019 in china

Clinical features of patients infected with 2019 novel 600 coronavirus in wuhan, china

Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia

Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: a retrospective cohort study

2019-ncov: preliminary estimates of the confirmed-casefatality-ratio and infection-fatality-ratio, and initial pandemic risk assessment

How will country-based mitigation measures influence the course of the 615 covid-19 epidemic?

What will be the economic impact of covid-19 in the us? rough estimates of disease scenarios

Covid-19-the law and limits of quarantine

Covid-19 coronavirus outbreak

Improved molecular diagnosis of covid-19 by the novel, highly sensitive and specific covid-19-rdrp/hel real-time reverse transcription-pcr assay validated in vitro and with clinical specimens

Evaluation of the effectiveness of surveillance and containment measures for the first 100 patients with covid-19 in singapore

Potential biases in estimating absolute and relative case-fatality risks during outbreaks

Methods for estimating the case 640 fatality ratio for a novel, emerging infectious disease

Covid-19 antibody seroprevalence in

Estimating the asymptomatic proportion of coronavirus disease 2019 (covid-19) cases on board the diamond princess cruise ship, yokohama, japan

Estimates of the severity of coronavirus disease 2019: a model-based analysis, The Lancet Infectious Diseases

Features, evaluation and treatment coronavirus (covid-19), in: Statpearls

Managing covid-19 in low-and middle-income countries

World Bank

World Bank, Population ages 65 and above

Mortality patterns in hypertension

Mortality 665 trends in men and women with diabetes

Covid-19 in italy: an analysis of death registry data

Estimates of the un-670 detected rate among the sars-cov-2 infected using testing data from iceland

Case-fatality rate and characteristics of patients dying in relation to covid-19 in italy

An empirical estimate of the infection fatality rate 675 of covid-19 from the first italian outbreak

Life with and without heart disease among women and men over 50